GlassScriptPhysician profile
Teresa Marshall
NPI 1346257565
$16,250.10
in general payments reported to CMS, 2019-2025
57 companies · $2,279 in 2025
The $2,279 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,699 · 2020: $1,776 · 2021: $2,143 · 2022: $1,605 · 2023: $2,771 · 2024: $2,976 · 2025: $2,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,962 · Education: $64.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,961.82 |
| Education | $64.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,114.46 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,644.96 | 2021-2025 | |
| Lilly USA, LLC | $1,644.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,644.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,294.63 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $824.93 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $618.17 | 2019-2025 | Belsomra, Steglatro, Verquvo |
| Abbott Laboratories | $607.91 | 2021-2025 | Freestyle Libre 3, Eterna, Octrode |
| Amgen INC. | $525.90 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $517.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $458.13 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $408.35 | 2019-2025 | Veozah |
| Viiv Healthcare Company | $381.71 | 2023-2025 | Apretude |
| Sunovion Pharmaceuticals INC. | $335.71 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $301.99 | 2021-2024 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teresa Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.